GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (LSE:VRCI) » Definitions » Net Change in Cash

Verici Dx (LSE:VRCI) Net Change in Cash : £1.38 Mil (TTM As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Verici Dx Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Verici Dx's Net Change in Cash for the six months ended in Jun. 2024 was £3.43 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 was £1.38 Mil.

Verici Dx Net Change in Cash Historical Data

The historical data trend for Verici Dx's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Net Change in Cash Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Change in Cash
- -5.57 -0.44 -5.66

Verici Dx Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Change in Cash Get a 7-Day Free Trial 4.37 -4.85 -3.61 -2.06 3.43

Verici Dx Net Change in Cash Calculation

Verici Dx's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-5.656+-0.182+-0.021+0.204
=-5.66

Verici Dx's Net Change in Cash for the quarter that ended in Jun. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-2.497+-0.075+5.923+0.083
=3.43

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was £1.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Verici Dx Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Verici Dx's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (LSE:VRCI) » Definitions » Net Change in Cash
Comparable Companies
LSE:GENI LSE:GDR LSE:PRM LSE:LLAI LSE:ABDX TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD NTRA WAT DGX LH XPAR:BIM ILMN ICLR
Traded in Other Exchanges
63V:Germany
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Website
https://www.vericidx.com
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines